DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.

Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Attention Deficit Hyperactivity Disorder

Intervention: Naltrexone (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Massachusetts General Hospital

Official(s) and/or principal investigator(s):
Thomas Spencer, MD, Principal Investigator, Affiliation: Massachusetts General Hospital

Overall contact:
Jessica Abrams, BA, Phone: 617-726-0142, Email: jmabrams@mgh.harvard.edu

Summary

The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating ADHD in adults. Medications that increase dopamine are often effective in treating ADHD in adults. Since naltrexone is a kappa opioid receptor antagonist, it increases dopamine in the brain. We predict that naltrexone as a monotherapy will be effective for ADHD symptoms in adults with ADHD. We also plan to assess the effects of naltrexone on dopamine as measured by changes in serum prolactin. We predict that naltrexone will increase dopamine as indexed by decreases in serum prolactin.

Clinical Details

Official title: An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Adult Investigator Symptom Rating Scale (AISRS)

Secondary outcome: Clinical Global Impression (CGI)

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria

- Male and female outpatients 18-55 years of age.

- Diagnosis of ADHD, by DSM-IV by clinical evaluation by an expert clinician.

- Subjects treated for anxiety disorders and depression who are on a stable medication

regimen for at least one month, and who have a disorder-specific CGI-Severity score ≤ 3 (mildly ill) and who have a score on the Hamilton-Depression and Hamilton-Anxiety rating scales below 15 (mild range). Exclusion Criteria

- Any clinically unstable psychiatric conditions including any history of psychosis or

mania, suicidality, sociopathy, criminality, or delinquency.

- Current (last 3 months) substance use disorders (alcohol or drugs),

- Medical condition or treatment that will either jeopardize subject safety or affect

the scientific merit of the study including cardiovascular disease, current untreated hypertension, history of renal or hepatic impairment, or a condition that will or may require treatment with opioid analgesics.

- Clinically significant abnormal baseline laboratory LFT's, which is defined as LFT's

greater than the ULN.

- Mental retardation (IQ < 80).

- Organic brain disorders including delirium, dementia, seizures, stroke, neurosurgery,

and head trauma with loss of consciousness.

- Pregnant or nursing females.

- Subjects with current adequate treatment for ADHD.

- Current treatment with medication for ADHD.

- Any other concomitant medication with primarily central nervous system activity other

than specified in the protocol (a stable and effective treatment regimen of an SSRI or benzodiazepine is permitted per clinical review.)

- A Clinical Global Impression (CGI) of 7 (among the most extremely ill patients) at

the screening visit is exclusionary, and any subject who presents a CGI-S of 7 at any point during the study will be removed from participation.

- Subjects presenting with a CGI-Severity score of 6 (severely ill) at two consecutive

visits after week 2 will be dropped from the study (i. e. A subject with a CGI of 6 at his/her week 3 visit and at week 4 visit will be dropped from the study at the week 4 visit). Subjects who are dropped for severe or worsening symptoms after exposure to the study medication will receive free follow up care as described in the detailed protocol and protocol summary.

- Non-English speaking subjects

Locations and Contacts

Jessica Abrams, BA, Phone: 617-726-0142, Email: jmabrams@mgh.harvard.edu

Massachusetts General Hospital, Boston, Massachusetts 02114, United States; Recruiting
Jessica Abrams, BA, Phone: 617-726-0142, Email: jmabrams@mgh.harvard.edu
Leah Feinberg, BS, Phone: 617-726-4651, Email: lkfeinberg@mgh.harvard.edu
Thomas Spencer, MD, Principal Investigator
Additional Information

Starting date: November 2013
Last updated: March 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017